Merck & Co., Inc.

NYSE:MRK 주식 리포트

시가총액: US$271.8b

Merck 과거 순이익 실적

과거 기준 점검 5/6

Merck은 연평균 18.1%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 10.3% 증가했습니다. 매출은 연평균 8.1%의 비율로 증가했습니다. Merck의 자기자본이익률은 34.7%이고 순이익률은 28.1%입니다.

핵심 정보

18.12%

순이익 성장률

18.25%

주당순이익(EPS) 성장률

Pharmaceuticals 산업 성장률5.95%
매출 성장률8.11%
자기자본이익률34.68%
순이익률28.08%
다음 순이익 업데이트30 Apr 2026

최근 과거 실적 업데이트

Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Aug 12
Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Recent updates

Merck: Bullish Setup Into Q1 Earnings

Apr 27

Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)

Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.

MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple

Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.

MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside

Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.

MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple

The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.

MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside

Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.

MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance

Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.

MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple

Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.

The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff

Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.

MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance

Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.

MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes

Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.

MRK: Cidara Flu Deal Will Likely Expose Overstated Long Term Expectations

Analysts have nudged their fair value estimate for Merck higher, lifting the price target by $1 to $83 as they factor in stronger revenue growth, improved profit margins, and a lower future P/E multiple supported by recent positive research initiations and deal activity. Analyst Commentary Street research around Merck has turned more constructive in recent weeks, with several firms highlighting an improving growth outlook and a more attractive risk reward profile.

Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs

based on Q3 result

MRK: Cidara Acquisition And Patent Overhang Will Shape Future Risk Reward Balance

Analysts have modestly raised their fair value estimate for Merck to approximately $106.62 from about $104.27 per share, citing the higher Street price target of $105, growing confidence in its infectious disease and oncology pipeline, and the view that shares remain attractively valued relative to the company's long term growth prospects. Analyst Commentary Street research on Merck continues to highlight a constructive long term outlook balanced by execution and concentration risks, with recent notes refining expectations around valuation, pipeline durability, and capital allocation.

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Dec 02
Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

MRK: Recent Pipeline Deals And Patent Expiry Will Shape Outlook Ahead

Analysts have raised the price target for Merck to $105 from $98, citing stronger growth prospects and a more favorable valuation because of the company’s expanding pipeline and recent strategic deals. Analyst Commentary Recent analyst commentary on Merck highlights both positive momentum and notable risks that could influence the company’s trajectory in the months ahead.

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 02
Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

US Investments And New Product Launches Will Shape Future Markets

Merck’s analyst price target edged up to $101.75, driven by positive sentiment around the Verona Pharma acquisition’s boost to the respiratory portfolio, ongoing digital and oncology partnerships, and stable vaccine outlook. Analyst Commentary Bullish analysts point to Merck’s $10B acquisition of Verona Pharma, seeing Verona’s Ohtu as a strategic anchor drug to expand Merck’s respiratory franchise and enhance competitiveness against major therapeutics in the space.

Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Aug 12
Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

매출 및 비용 세부 내역

Merck가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NYSE:MRK 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
31 Dec 2565,01118,25410,11515,614
30 Sep 2564,23519,03410,07312,746
30 Jun 2563,61616,40610,13515,163
31 Mar 2563,92217,43410,18614,668
31 Dec 2464,16817,11710,10014,481
30 Sep 2463,17412,14810,05022,200
30 Jun 2462,48013,7369,84718,868
31 Mar 2461,4032,3069,83918,592
31 Dec 2360,1153659,88418,342
30 Sep 2359,3154,6089,83912,556
30 Jun 2358,3113,1119,93412,881
31 Mar 2357,86913,0309,85112,433
31 Dec 2259,28314,5199,66911,918
30 Sep 2258,97415,3229,84011,923
30 Jun 2257,16916,6419,77610,940
31 Mar 2253,97813,9109,48910,515
31 Dec 2148,70412,3459,40311,942
30 Sep 2146,1315,9089,26010,725
30 Jun 2143,9063,6658,84510,678
31 Mar 2141,8574,7938,66910,339
31 Dec 2041,5184,5198,56910,564
30 Sep 2042,4389,4928,8129,079
30 Jun 2043,9069,0709,2008,818
31 Mar 2046,3129,3999,7008,990
31 Dec 1939,1215,6908,8298,594
30 Sep 1945,9709,3149,6048,489
30 Jun 1944,3679,3629,5867,997
31 Mar 1943,0738,3999,4678,084
31 Dec 1842,2946,2209,5879,254
30 Sep 1841,7293,3479,5419,251
30 Jun 1841,2591,3419,55411,680
31 Mar 1840,7251,5799,44911,182
31 Dec 1740,1222,3949,5609,845
30 Sep 1739,8042,8459,6159,427
30 Jun 1740,0165,0869,6126,916
31 Mar 1739,9294,3469,7137,035
31 Dec 1639,8073,9209,3136,921
30 Sep 1639,9075,4929,1936,849
30 Jun 1639,4445,1339,3126,828
31 Mar 1639,3854,6149,7766,518
31 Dec 1539,4984,4429,7996,613
30 Sep 1539,76510,78110,2626,727
30 Jun 1540,2499,85010,7566,644

양질의 수익: MRK는 고품질 수익을 보유하고 있습니다.

이익 마진 증가: MRK의 현재 순 이익률 (28.1%)은 지난해 (26.7%)보다 높습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: MRK의 수익은 지난 5년 동안 연평균 18.1% 증가했습니다.

성장 가속화: 지난 1년간 MRK 의 수익 증가율(6.6%)은 5년 평균(연간 18.1%)보다 낮습니다.

수익 대 산업: MRK의 지난 1년 수익 증가율(6.6%)은 Pharmaceuticals 업계의 -3.2%를 상회했습니다.

자기자본이익률

높은 ROE: MRK의 자본 수익률(34.7%)은 높음으로 평가됩니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/04/29 14:13
종가2026/04/29 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Merck & Co., Inc.는 49명의 분석가가 다루고 있습니다. 이 중 21명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
David ToungArgus Research Company
Charles ButlerBarclays
Emily FieldBarclays